
According to data from Benzinga Pro, during Q1, NovoCure's (NASDAQ:NVCR) reported sales totaled $137.55 million. Despite a 82.44% increase in earnings, the company posted a loss of $4.65 million. NovoCure collected $133.21 million in revenue during Q4, but reported earnings showed a $26.46 million loss.